← Back to all signals
JNJ · Q2 2026

Johnson & Johnson

Reported 2026-07-15
IN-LINE
51EarnIQ signal
↗

Confidence rising

Mild quarter-over-quarter shift

Strong Q2 results and raised guidance confirm robust operational momentum toward the $100 billion annual revenue milestone.

  • ✓Guidance was raised, with high specificity.
  • ✓Management tone registered as confident (85/100).
  • ✓EarnIQ detected 0 potential management deflections.
Headline–confidence gap

Mixed evidence

The headline and management signals do not point in one direction (confidence rising).

EPS: reported vs expected+0.9%$2.90 vs $2.87
Revenue: reported vs expected—— vs —
Guidance specificityHighRaised
Market expectations supplied by Finnhub · Reported vs consensus estimate

With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.

Premium intelligence

The evidence behind the signal

Full report
Management language

Why confidence moved

“Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges”
“With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.”
“Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint.”
Guidance specificity
90/100

High specificity

Increased full-year 2026 estimated reported sales to $101.1 billion at the midpoint and adjusted EPS guidance to $11.68.

Pressure point
!

STELARA patent expiration and biosimilar

0 potential deflections detected in management communication.

Narrative break

What changed

Agreement to acquire Firefly Bio, Inc. to expand oncology pipeline with novel degrader antibody conjugate platform.

Q&A evidence

Management responses

No material Q&A deflections were detected.

Key positives
  • Q2 reported sales grew 6.6% to $25.3 billion, putting the company on track to surpass $100 billion in annual revenue for the first time.
  • Full-year 2026 guidance was raised, with estimated reported sales increased to $101.1 billion at the midpoint and adjusted EPS increased to $11.68.
  • Robust pipeline progress and regulatory approvals including TREMFYA, CAPLYTA, and the Dual Energy THERMOCOOL SMARTTOUCH SF platform.
Key risks
  • STELARA patent expiration and biosimilar competition causing an approximate 760 basis points impact on Innovative Medicine operational sales growth.
  • Uncertainty around the ultimate outcome of legal proceedings, unusual gains and losses, and acquisition-related expenses.
  • Foreign exchange volatility and translational currency impact on international and worldwide reported sales.
Topic velocity

Language versus prior quarter

M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition

What drove the EarnIQ score

Tone+20
Eps Beat+0
Guidance+15
New Signal+8
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0